摘要
目的:探讨冠心病(CHD)合并糖耐量受损患者的血清脂联素和瘦素水平及阿卡波糖的干预效果。方法:将46例CHD患者按照口服葡萄糖耐量(OGTT)试验分为单纯CHD组(27例)和CHD伴糖耐量受损(IGT)组(19例),33例体检者也根据OGTT试验分为正常对照组(18例)和单纯IGT组(15例)。测定受试者血清脂联素和瘦素水平,记录OGTT试验结果,检测血脂、超敏C反应蛋白(hs-CRP)、空腹胰岛素,并测量身高、体重、腰围等。对CHD并IGT组和单纯IGT组均给予阿卡波糖干预3个月后复测上述指标。结果:血清脂联素水平在CHD患者中降低,合并IGT时更加显著,其水平与HDL-C、HOMA-IR、SBP及性别相关。血清瘦素水平在IGT患者中升高,其水平与腰围、BMI相关,女性显著高于男性。经阿卡波糖干预后,血清脂联素水平显著升高,TC的变化与其升高的水平相关;血清瘦素水平降低,女性降低更甚。结论:阿卡波糖可改变CHD合并IGT患者血清脂联素和瘦素水平,并可能通过其变化来改善餐后高血糖、血脂紊乱、肥胖及胰岛素抵抗等,从而发挥其心血管保护作用。
Objective：To investigate the influence of acarbose on serum adiponectin and leptin levers in patient of coronary heart disease （CHD） complicated with impaired glucose tolerance （IGT）. Method： The 46 CHD patients were divided into two groups by OGTT： simple CHD（n=27）, CHD with IGT （n=19）. And 33 health volunteers were divided into two groups., simple IGT （n= 15）, normal control （n= 18）. The enzyme linked immu- nosorbent assay （ELISA） were used to measure the fasting serum levers of adiponectin and leptin, and fasting insulin （Fins）, blood-lipid level, hs-CRP. The body height, body weight, waist circumference were obtained when the patients were enrolled. Result：The serum levers of adiponectin were reduced in patients with CHD, and the levers became lower when the subjects with IGT together. After the acarbose intervention, the serum levers of adiponectin were higher, and were correlated with the changes of TG; the leptin levers were lower, and the chan- ges were higher in women than men. Conclusion： Acarbose may influent the serum levers of adiponectin and leptin, which may improve obesity and postprandial, and protect patients with CHD complicated with IGT.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2014年第3期244-247,共4页
Journal of Clinical Cardiology
基金
CGICC医学科研支持计划专项资金项目资助(No:08010028)
广东省自然科学基金资助(No:9151009101000016)
关键词
冠心病
阿卡波糖
糖耐量受损
脂联素
瘦素
coronary disease
acarbose
impaired glucose tolerance
adiponectin
leptin
